ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells

Reuben Kapur, Jianjian Shi, Joydeep Ghosh, Veerendra Munugalavadla, Emily Sims, Holly Martin, Lei Wei, Raghuveer Singh Mali

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Understanding mast cell development is essential due to their critical role in regulating immunity and autoimmune diseases. Here, we show how Rho kinases (ROCK) regulate mast cell development and can function as therapeutic targets for treating allergic diseases. Rock1 deficiency results in delayed maturation of bone marrow derived mast cells (BMMCs) in response to IL-3 stimulation and reduced growth in response to stem cell factor (SCF) stimulation. Further, integrin-mediated adhesion and migration, and IgE-mediated degranulation are all impaired in Rock1-deficient BMMCs. To understand the mechanism behind altered mast cell development in Rock1-/- BMMCs, we analyzed the activation of ROCK and its downstream targets including LIM kinase (LIMK). We observed reduced activation of ROCK, LIMK, AKT and ERK1/2 in Rock1-deficient BMMCs in response to SCF stimulation. Further, loss of either Limk1 or Limk2 also demonstrated altered BMMC maturation and growth; combined deletion of both Limk1 and Limk2 resulted in further reduction in BMMC maturation and growth. In passive cutaneous anaphylaxis model, deficiency of Rock1 or treatment with ROCK inhibitor Fasudil protected mice against IgE-mediated challenge. Our results identify ROCK/LIMK pathway as a novel therapeutic target for treating allergic diseases involving mast cells.

Original languageEnglish (US)
Pages (from-to)16936-16947
Number of pages12
JournalOncotarget
Volume7
Issue number13
DOIs
StatePublished - Mar 29 2016

Fingerprint

Lim Kinases
Mast Cells
Actins
Growth
Bone Marrow
Stem Cell Factor
Immunoglobulin E
Mastocytosis
rho-Associated Kinases
Passive Cutaneous Anaphylaxis
Interleukin-3
Integrins
Autoimmune Diseases
Immunity

Keywords

  • Anaphylaxis
  • Cell growth
  • LIM kinase
  • Mast cells
  • Rho kinase

ASJC Scopus subject areas

  • Oncology

Cite this

ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells. / Kapur, Reuben; Shi, Jianjian; Ghosh, Joydeep; Munugalavadla, Veerendra; Sims, Emily; Martin, Holly; Wei, Lei; Mali, Raghuveer Singh.

In: Oncotarget, Vol. 7, No. 13, 29.03.2016, p. 16936-16947.

Research output: Contribution to journalArticle

Kapur, Reuben ; Shi, Jianjian ; Ghosh, Joydeep ; Munugalavadla, Veerendra ; Sims, Emily ; Martin, Holly ; Wei, Lei ; Mali, Raghuveer Singh. / ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells. In: Oncotarget. 2016 ; Vol. 7, No. 13. pp. 16936-16947.
@article{df1f317105f24d709db71a00c663307f,
title = "ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells",
abstract = "Understanding mast cell development is essential due to their critical role in regulating immunity and autoimmune diseases. Here, we show how Rho kinases (ROCK) regulate mast cell development and can function as therapeutic targets for treating allergic diseases. Rock1 deficiency results in delayed maturation of bone marrow derived mast cells (BMMCs) in response to IL-3 stimulation and reduced growth in response to stem cell factor (SCF) stimulation. Further, integrin-mediated adhesion and migration, and IgE-mediated degranulation are all impaired in Rock1-deficient BMMCs. To understand the mechanism behind altered mast cell development in Rock1-/- BMMCs, we analyzed the activation of ROCK and its downstream targets including LIM kinase (LIMK). We observed reduced activation of ROCK, LIMK, AKT and ERK1/2 in Rock1-deficient BMMCs in response to SCF stimulation. Further, loss of either Limk1 or Limk2 also demonstrated altered BMMC maturation and growth; combined deletion of both Limk1 and Limk2 resulted in further reduction in BMMC maturation and growth. In passive cutaneous anaphylaxis model, deficiency of Rock1 or treatment with ROCK inhibitor Fasudil protected mice against IgE-mediated challenge. Our results identify ROCK/LIMK pathway as a novel therapeutic target for treating allergic diseases involving mast cells.",
keywords = "Anaphylaxis, Cell growth, LIM kinase, Mast cells, Rho kinase",
author = "Reuben Kapur and Jianjian Shi and Joydeep Ghosh and Veerendra Munugalavadla and Emily Sims and Holly Martin and Lei Wei and Mali, {Raghuveer Singh}",
year = "2016",
month = "3",
day = "29",
doi = "10.18632/oncotarget.7851",
language = "English (US)",
volume = "7",
pages = "16936--16947",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "13",

}

TY - JOUR

T1 - ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells

AU - Kapur, Reuben

AU - Shi, Jianjian

AU - Ghosh, Joydeep

AU - Munugalavadla, Veerendra

AU - Sims, Emily

AU - Martin, Holly

AU - Wei, Lei

AU - Mali, Raghuveer Singh

PY - 2016/3/29

Y1 - 2016/3/29

N2 - Understanding mast cell development is essential due to their critical role in regulating immunity and autoimmune diseases. Here, we show how Rho kinases (ROCK) regulate mast cell development and can function as therapeutic targets for treating allergic diseases. Rock1 deficiency results in delayed maturation of bone marrow derived mast cells (BMMCs) in response to IL-3 stimulation and reduced growth in response to stem cell factor (SCF) stimulation. Further, integrin-mediated adhesion and migration, and IgE-mediated degranulation are all impaired in Rock1-deficient BMMCs. To understand the mechanism behind altered mast cell development in Rock1-/- BMMCs, we analyzed the activation of ROCK and its downstream targets including LIM kinase (LIMK). We observed reduced activation of ROCK, LIMK, AKT and ERK1/2 in Rock1-deficient BMMCs in response to SCF stimulation. Further, loss of either Limk1 or Limk2 also demonstrated altered BMMC maturation and growth; combined deletion of both Limk1 and Limk2 resulted in further reduction in BMMC maturation and growth. In passive cutaneous anaphylaxis model, deficiency of Rock1 or treatment with ROCK inhibitor Fasudil protected mice against IgE-mediated challenge. Our results identify ROCK/LIMK pathway as a novel therapeutic target for treating allergic diseases involving mast cells.

AB - Understanding mast cell development is essential due to their critical role in regulating immunity and autoimmune diseases. Here, we show how Rho kinases (ROCK) regulate mast cell development and can function as therapeutic targets for treating allergic diseases. Rock1 deficiency results in delayed maturation of bone marrow derived mast cells (BMMCs) in response to IL-3 stimulation and reduced growth in response to stem cell factor (SCF) stimulation. Further, integrin-mediated adhesion and migration, and IgE-mediated degranulation are all impaired in Rock1-deficient BMMCs. To understand the mechanism behind altered mast cell development in Rock1-/- BMMCs, we analyzed the activation of ROCK and its downstream targets including LIM kinase (LIMK). We observed reduced activation of ROCK, LIMK, AKT and ERK1/2 in Rock1-deficient BMMCs in response to SCF stimulation. Further, loss of either Limk1 or Limk2 also demonstrated altered BMMC maturation and growth; combined deletion of both Limk1 and Limk2 resulted in further reduction in BMMC maturation and growth. In passive cutaneous anaphylaxis model, deficiency of Rock1 or treatment with ROCK inhibitor Fasudil protected mice against IgE-mediated challenge. Our results identify ROCK/LIMK pathway as a novel therapeutic target for treating allergic diseases involving mast cells.

KW - Anaphylaxis

KW - Cell growth

KW - LIM kinase

KW - Mast cells

KW - Rho kinase

UR - http://www.scopus.com/inward/record.url?scp=84971673792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971673792&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7851

DO - 10.18632/oncotarget.7851

M3 - Article

C2 - 26943578

AN - SCOPUS:84971673792

VL - 7

SP - 16936

EP - 16947

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -